Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.

Kohaar I, Petrovics G, Srivastava S.

Int J Mol Sci. 2019 Apr 12;20(8). pii: E1813. doi: 10.3390/ijms20081813. Review.

2.

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.

Petrovics G, Price DK, Lou H, Chen Y, Garland L, Bass S, Jones K, Kohaar I, Ali A, Ravindranath L, Young D, Cullen J, Dorsey TH, Sesterhenn IA, Brassell SA, Rosner IL, Ross D, Dahut W, Ambs S, Figg WD, Srivastava S, Dean M.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):406-410. doi: 10.1038/s41391-018-0114-1. Epub 2018 Dec 12.

3.

Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.

Mohamed AA, Xavier CP, Sukumar G, Tan SH, Ravindranath L, Seraj N, Kumar V, Sreenath T, McLeod DG, Petrovics G, Rosner IL, Srivastava M, Strovel J, Malhotra SV, LaRonde NA, Dobi A, Dalgard CL, Srivastava S.

Cancer Res. 2018 Jul 1;78(13):3659-3671. doi: 10.1158/0008-5472.CAN-17-2949. Epub 2018 Apr 30.

4.

Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities.

Tan SH, Petrovics G, Srivastava S.

Int J Mol Sci. 2018 Apr 22;19(4). pii: E1255. doi: 10.3390/ijms19041255. Review.

5.

Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry.

Conti DV, Wang K, Sheng X, Bensen JT, Hazelett DJ, Cook MB, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Sanderson M, John EM, Park JY, Xu J, Stevens VL, Berndt SI, Huff CD, Wang Z, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Sellers TA, Yamoah K, Murphy AB, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Stern MC, Jarai ZK, Govindasami K, Chokkalingam AP, Hsing AW, Goodman PJ, Hoffmann T, Drake BF, Hu JJ, Clark PE, Van Den Eeden SK, Blanchet P, Fowke JH, Casey G, Hennis AJM, Han Y, Lubwama A, Thompson IM Jr, Leach R, Easton DF, Schumacher F, Van den Berg DJ, Gundell SM, Stram A, Wan P, Xia L, Pooler LC, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Srivastava S, Eeles RA, Carpten J, Kibel AS, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Klein EA, Brureau L, Stram DO, Watya S, Chanock SJ, Witte JS, Blot WJ, Henderson BE, Haiman CA; PRACTICAL/ELLIPSE Consortium.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx084.

6.

Re: Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.

McLeod DG, Petrovics G.

Eur Urol. 2018 Feb;73(2):301-302. doi: 10.1016/j.eururo.2017.09.035. Epub 2017 Oct 14. No abstract available.

PMID:
29037514
7.

Erratum: ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.

Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T, Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G, Sesterhenn IA, Rosner IL, Bieberich CJ, Nelson P, Vasioukhin V, Srivastava S.

Sci Rep. 2017 Sep 6;7(1):10693. doi: 10.1038/s41598-017-09612-4.

8.

Is non-pharmacological treatment an effective option for chronic low back pain?

Ondrejkovicova A, Petrovics G, Svitkova K, Balogh V.

Neuro Endocrinol Lett. 2017 Jul;38(3):169-172.

PMID:
28759184
9.

Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

Cullen J, Young D, Chen Y, Degon M, Farrell J, Sedarsky J, Baptiste W, Rosen P, Tolstikov V, Kiebish M, Kagan J, Srivastava S, Kuo HC, Moncur JT, Rosner IL, Narain N, Akmaev V, Petrovics G, Dobi A, McLeod DG, Srivastava S, Sesterhenn IA.

Eur Urol Focus. 2018 Dec;4(6):818-824. doi: 10.1016/j.euf.2017.02.016. Epub 2017 Mar 11.

PMID:
28753864
10.

Multiple sclerosis in an acupuncture practice.

Petrovics G, Ondrejkovicova A.

Neuro Endocrinol Lett. 2017 May;38(2):87-90.

PMID:
28650601
11.

Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.

Mohamed AA, Tan SH, Xavier CP, Katta S, Huang W, Ravindranath L, Jamal M, Li H, Srivastava M, Srivatsan ES, Sreenath TL, McLeod DG, Srinivasan A, Petrovics G, Dobi A, Srivastava S.

Mol Cancer Res. 2017 Oct;15(10):1308-1317. doi: 10.1158/1541-7786.MCR-17-0058. Epub 2017 Jun 12.

12.

ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.

Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T, Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G, Sesterhenn IA, Rosner IL, Bieberich CJ, Nelson P, Vasioukhin V, Srivastava S.

Sci Rep. 2017 Apr 24;7(1):1109. doi: 10.1038/s41598-017-01187-4. Erratum in: Sci Rep. 2017 Sep 6;7(1):10693.

13.

Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.

Rastogi A, Ali A, Tan SH, Banerjee S, Chen Y, Cullen J, Xavier CP, Mohamed AA, Ravindranath L, Srivastav J, Young D, Sesterhenn IA, Kagan J, Srivastava S, McLeod DG, Rosner IL, Petrovics G, Dobi A, Srivastava S, Srinivasan A.

Genes Cancer. 2016 Nov;7(11-12):394-413. doi: 10.18632/genesandcancer.126.

14.

Why acupuncture in pain treatment?

Ondrejkovicova A, Petrovics G, Svitkova K, Bajtekova B, Bangha O.

Neuro Endocrinol Lett. 2016 Jul;37(3):163-168. Review.

PMID:
27618609
15.

Activation of endogenous TRPV1 fails to induce overstimulation-based cytotoxicity in breast and prostate cancer cells but not in pain-sensing neurons.

Pecze L, Jósvay K, Blum W, Petrovics G, Vizler C, Oláh Z, Schwaller B.

Biochim Biophys Acta. 2016 Aug;1863(8):2054-64. doi: 10.1016/j.bbamcr.2016.05.007. Epub 2016 May 11.

16.

Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1.

Kumar P, Sharad S, Petrovics G, Mohamed A, Dobi A, Sreenath TL, Srivastava S, Biswas R.

Oncotarget. 2016 Apr 19;7(16):22791-806. doi: 10.18632/oncotarget.8061.

17.

A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men.

Petrovics G, Li H, Stümpel T, Tan SH, Young D, Katta S, Li Q, Ying K, Klocke B, Ravindranath L, Kohaar I, Chen Y, Ribli D, Grote K, Zou H, Cheng J, Dalgard CL, Zhang S, Csabai I, Kagan J, Takeda D, Loda M, Srivastava S, Scherf M, Seifert M, Gaiser T, McLeod DG, Szallasi Z, Ebner R, Werner T, Sesterhenn IA, Freedman M, Dobi A, Srivastava S.

EBioMedicine. 2015 Oct 31;2(12):1957-64. doi: 10.1016/j.ebiom.2015.10.028. eCollection 2015 Dec.

18.

Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods.

He J, Schepmoes AA, Shi T, Wu C, Fillmore TL, Gao Y, Smith RD, Qian WJ, Rodland KD, Liu T, Camp DG 2nd, Rastogi A, Tan SH, Yan W, Mohamed AA, Huang W, Banerjee S, Kagan J, Srivastava S, McLeod DG, Srivastava S, Petrovics G, Dobi A, Srinivasan A.

J Transl Med. 2015 Feb 12;13:54. doi: 10.1186/s12967-015-0418-z.

19.

Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.

Li H, Mohamed AA, Sharad S, Umeda E, Song Y, Young D, Petrovics G, McLeod DG, Sesterhenn IA, Sreenath T, Dobi A, Srivastava S.

Oncotarget. 2015 Jun 20;6(17):15137-49.

20.

Prostate cancer marker panel with single cell sensitivity in urine.

Nickens KP, Ali A, Scoggin T, Tan SH, Ravindranath L, McLeod DG, Dobi A, Tacha D, Sesterhenn IA, Srivastava S, Petrovics G.

Prostate. 2015 Jun 15;75(9):969-75. doi: 10.1002/pros.22981. Epub 2015 Mar 23.

21.

A long noncoding RNA connects c-Myc to tumor metabolism.

Hung CL, Wang LY, Yu YL, Chen HW, Srivastava S, Petrovics G, Kung HJ.

Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18697-702. doi: 10.1073/pnas.1415669112. Epub 2014 Dec 15.

22.

ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer.

Griner NB, Young D, Chaudhary P, Mohamed AA, Huang W, Chen Y, Sreenath T, Dobi A, Petrovics G, Vishwanatha JK, Sesterhenn IA, Srivastava S, Tan SH.

Mol Cancer Res. 2015 Feb;13(2):368-79. doi: 10.1158/1541-7786.MCR-14-0275-T. Epub 2014 Oct 24.

23.

Predominance of ERG-negative high-grade prostate cancers in African American men.

Farrell J, Young D, Chen Y, Cullen J, Rosner IL, Kagan J, Srivastava S, McLEOD DG, Sesterhenn IA, Srivastava S, Petrovics G.

Mol Clin Oncol. 2014 Nov;2(6):982-986. Epub 2014 Aug 7.

24.

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer.

Rastogi A, Tan SH, Mohamed AA, Chen Y, Hu Y, Petrovics G, Sreenath T, Kagan J, Srivastava S, McLeod DG, Sesterhenn IA, Srivastava S, Dobi A, Srinivasan A.

Genes Cancer. 2014 Jul;5(7-8):273-84.

25.

Long noncoding RNA-mediated activation of androgen receptor in prostate cancer.

Petrovics G, Srivastava S.

Asian J Androl. 2014 May-Jun;16(3):418-9. doi: 10.4103/1008-682X.126398. No abstract available.

26.

Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer.

Sharad S, Ravindranath L, Haffner MC, Li H, Yan W, Sesterhenn IA, Chen Y, Ali A, Srinivasan A, McLeod DG, Yegnasubramanian S, Srivastava S, Dobi A, Petrovics G.

Epigenetics. 2014 Jun;9(6):918-27. doi: 10.4161/epi.28710. Epub 2014 Apr 2.

27.

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.

Thangapazham R, Saenz F, Katta S, Mohamed AA, Tan SH, Petrovics G, Srivastava S, Dobi A.

BMC Cancer. 2014 Jan 13;14:16. doi: 10.1186/1471-2407-14-16.

28.

Evaluation of ERG responsive proteome in prostate cancer.

Tan SH, Furusato B, Fang X, He F, Mohamed AA, Griner NB, Sood K, Saxena S, Katta S, Young D, Chen Y, Sreenath T, Petrovics G, Dobi A, McLeod DG, Sesterhenn IA, Saxena S, Srivastava S.

Prostate. 2014 Jan;74(1):70-89. doi: 10.1002/pros.22731. Epub 2013 Sep 21.

29.

TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.

Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, Maloff C, Srigley J, Joshua AM, Petrovics G, van der Kwast T, Evans A, Milosevic M, Saad F, Collins C, Squire J, Lam W, Bismar TA, Boutros PC, Bristow RG.

Clin Cancer Res. 2013 Sep 15;19(18):5202-9. doi: 10.1158/1078-0432.CCR-13-1049. Epub 2013 Aug 5.

30.

Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India.

Rawal S, Young D, Williams M, Colombo M, Krishnappa R, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA.

J Cancer. 2013 Jul 5;4(6):468-72. doi: 10.7150/jca.6568. Print 2013.

31.

Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men.

Farrell J, Petrovics G, McLeod DG, Srivastava S.

Int J Mol Sci. 2013 Jul 25;14(8):15510-31. doi: 10.3390/ijms140815510. Review.

32.

Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.

Rosen P, Pfister D, Young D, Petrovics G, Chen Y, Cullen J, Böhm D, Perner S, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S.

Urology. 2012 Oct;80(4):749-53. doi: 10.1016/j.urology.2012.07.001. Epub 2012 Aug 28.

33.

TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.

Casey OM, Fang L, Hynes PG, Abou-Kheir WG, Martin PL, Tillman HS, Petrovics G, Awwad HO, Ward Y, Lake R, Zhang L, Kelly K.

PLoS One. 2012;7(7):e41668. doi: 10.1371/journal.pone.0041668. Epub 2012 Jul 30.

34.

Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression.

Derosa CA, Furusato B, Shaheduzzaman S, Srikantan V, Wang Z, Chen Y, Seifert M, Ravindranath L, Young D, Nau M, Dobi A, Werner T, McLeod DG, Vahey MT, Sesterhenn IA, Srivastava S, Petrovics G.

Prostate Cancer Prostatic Dis. 2012 Jun;15(2):150-6. doi: 10.1038/pcan.2011.61. Epub 2011 Nov 29. Erratum in: Prostate Cancer Prostatic Dis. 2012 Jun;15(2):210. Siefert, M [corrected to Seifert, M].

PMID:
22343836
35.

Oncogenic activation of ERG: A predominant mechanism in prostate cancer.

Sreenath TL, Dobi A, Petrovics G, Srivastava S.

J Carcinog. 2011;10:37. doi: 10.4103/1477-3163.91122. Epub 2011 Dec 31.

36.

Highlights from the prostate cancer genome report.

Tan SH, Petrovics G, Srivastava S.

Asian J Androl. 2011 Sep;13(5):659-60. doi: 10.1038/aja.2011.84. Epub 2011 Jun 13. No abstract available.

37.

ERG oncogene modulates prostaglandin signaling in prostate cancer cells.

Mohamed AA, Tan SH, Sun C, Shaheduzzaman S, Hu Y, Petrovics G, Chen Y, Sesterhenn IA, Li H, Sreenath T, McLeod DG, Dobi A, Srivastava S.

Cancer Biol Ther. 2011 Feb 15;11(4):410-7. Epub 2011 Feb 15.

38.

Prostate cancer gene expression signature of patients with high body mass index.

Sharad S, Srivastava A, Ravulapalli S, Parker P, Chen Y, Li H, Petrovics G, Dobi A.

Prostate Cancer Prostatic Dis. 2011 Mar;14(1):22-9. doi: 10.1038/pcan.2010.44. Epub 2010 Nov 9.

39.

Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.

Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G.

Prostate Cancer Prostatic Dis. 2010 Dec;13(4):311-5. doi: 10.1038/pcan.2010.31. Epub 2010 Sep 7.

PMID:
20820186
40.

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.

Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, Thangapazham R, Chen Y, McMaster G, Sreenath T, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA.

Prostate Cancer Prostatic Dis. 2010 Sep;13(3):228-37. doi: 10.1038/pcan.2010.23. Epub 2010 Jun 29.

41.

Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.

Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M, Elsamanoudi S, Brassell S, Furusato B, Stingle N, Sesterhenn IA, Petrovics G, Miick S, Rittenhouse H, Groskopf J, McLeod DG, Srivastava S.

Clin Cancer Res. 2010 Mar 1;16(5):1572-6. doi: 10.1158/1078-0432.CCR-09-2191. Epub 2010 Feb 16.

42.

Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy.

Whitman EJ, Pomerantz M, Chen Y, Chamberlin MM, Furusato B, Gao C, Ali A, Ravindranath L, Dobi A, Sesterhenn IA, McLeod DG, Srivastava S, Freedman M, Petrovics G.

Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):1-8. doi: 10.1158/1055-9965.EPI-08-1111. Erratum in: Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):890. Sestrehenn, Isabell A [corrected to Sesterhenn, Isabell A].

43.

Osteoblast-specific factor 2 expression in prostate cancer-associated stroma: identification through microarray technology.

Furusato B, Tsunoda T, Shaheduzzaman S, Nau ME, Vahey M, Petrovics G, McLeod DG, Naito S, Shirasawa S, Srivastava S, Sesterhenn IA.

Urology. 2010 Apr;75(4):768-72. doi: 10.1016/j.urology.2009.10.026. Epub 2009 Dec 29.

PMID:
20035976
44.

The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research.

Brassell SA, Dobi A, Petrovics G, Srivastava S, McLeod D.

Urol Oncol. 2009 Sep-Oct;27(5):562-9. doi: 10.1016/j.urolonc.2009.01.023. Review.

PMID:
19720304
45.

Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status.

Mwamukonda K, Chen Y, Ravindranath L, Furusato B, Hu Y, Sterbis J, Osborn D, Rosner I, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G.

Prostate Cancer Prostatic Dis. 2010 Mar;13(1):47-51. doi: 10.1038/pcan.2009.28. Epub 2009 Jul 14.

46.

Evaluation of the 8q24 prostate cancer risk locus and MYC expression.

Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML.

Cancer Res. 2009 Jul 1;69(13):5568-74. doi: 10.1158/0008-5472.CAN-09-0387. Epub 2009 Jun 23.

47.

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG.

J Urol. 2008 Nov;180(5):1975-8; discussion 1978-9. doi: 10.1016/j.juro.2008.07.060. Epub 2008 Sep 17.

PMID:
18801539
48.

Delineation of TMPRSS2-ERG splice variants in prostate cancer.

Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L, Cullen J, Furusato B, Chen Y, Thangapazham RL, Mohamed A, Sun C, Sesterhenn IA, McLeod DG, Petrovics G, Srivastava S.

Clin Cancer Res. 2008 Aug 1;14(15):4719-25. doi: 10.1158/1078-0432.CCR-08-0531.

49.

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.

Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan SH, Vaidyanathan G, Whitman E, Hawksworth DJ, Chen Y, Nau M, Patel V, Vahey M, Gutkind JS, Sreenath T, Petrovics G, Sesterhenn IA, McLeod DG, Srivastava S.

Oncogene. 2008 Sep 11;27(40):5348-53. doi: 10.1038/onc.2008.183. Epub 2008 Jun 9.

PMID:
18542058
50.

Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis.

Liu AJ, Furusato B, Ravindranath L, Chen YM, Srikantan V, McLeod DG, Petrovics G, Srivastava S.

J Zhejiang Univ Sci B. 2007 Dec;8(12):853-9. doi: 10.1631/jzus.2007.B0853.

Supplemental Content

Loading ...
Support Center